Espero BioPharma   Report issue

For profit Phase 3
Founded: Jacksonville FL United States (2014)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
None
First Marketed Drug
2015
acetylsalicylic acid (aspirin)
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ESPERO

Active Ingredients

Marketed Drugs (1)

acetylsalicylic acid (aspirin) (2015)

Drugs in Phase 3 Trials (2)

Key: Espero BioPharma (0) Acquired (2)

tecarfarin (1 trial)

warfarin (coumadin) (1 trial)

Indications

Overview

  • Highest Phase: None
  • # of Trials: 1
  • # of Trial APIs: 2